Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]Chae HZ, Kim IH, Kim K, Rhee SG: Cloning, sequencing, and mutation of thiol-specific antioxidant gene of Saccharomyces cerevisiae. J Biol Chem 268, 16815-16821 (1993)

  • [2]Chae HZ, Kim IH, Kim K, Rhee SG: Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydro-peroxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci USA 91, 7017-7021 (1994)

  • [3]Chae HZ, Uhm TB, Rhee SG: Dimerization of thiol-specific antioxidant and the essential role of cysteine 47. Proc Natl Acad Sci USA 91, 7022-7026 (1994)

  • [4]Rhee SG, Woo HA: Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger H2O2, and protein chaperones. Antioxid Redox Signal 15, 781-794 (2011)

  • [5]Jeong JS, Kwon SJ, Kang SW, Rhee SG, Kim K: Purification and characterization of a second type thioredoxin peroxidase (type II TPx) from Saccharomyces cerevisiae. Biochemistry 38, 776-783 (1999)

  • [6]Salinas G, Fernández V, Fernández C, Selkirk ME: Echinococcus granulosus: Cloning of a thioredoxin peroxidase. Exp Parasitol 90, 298-301 (1998)

  • [7]Jin DY, Chae HZ, Rhee SG, Jeang KT: Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. J Biol Chem 272, 30952 – 30961 (1997)

  • [9]Butterfield LH, Merino A, Golub SH, Shau H: From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. Antioxid Redox Signal 1, 385-402 (1999)

  • [10]Lehtonen ST, Svensk AM, Soini Y, Pääkkö P, Hirvikoski P, Kang SW, Säily M, Kinnula VL: Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 111, 514-521 (2004)

  • [11]Hofmann B, Hecht HJ, Flohé L: Peroxiredoxins. Biol Chem 383, 347-364 (2002)

  • [12]Immenschuh S, Baumgart-Vogt E: Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 7, 768-777 (2005)

  • [13]Rhee SG, Chae HZ, Kim K: Peroxiredoxins: a historical overview and speculative preview of novel mechanismsand emerging concepts in cell signaling. Free Radic Biol Med 38, 1543-1552 (2005)

  • [14]Yi N, Xiao MB, Ni WK, Jiang F, Lu CH, Ni RZ: High expression of peroxiredoxin 4 affects the survival time of colorectal cancer patients, but is not an independent unfavorable prognostic factor. Mol Clin Oncol 2, 767-772 (2014)

  • [15]Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, Lilly MB, De León M, Casiano CA: Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate 71, 755-765 (2011)

  • [16]Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y: Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196, 316-323 (2002)

  • [17]Shiota M, Yokomizo A, Kashiwagi E, Takeuchi A, Fujimoto N, Uchiumi T, Naito S: Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. Free Radic Biol Med 51, 78-87 (2011)

  • [18]Ji D, Li M, Zhan T, Yao Y, Shen J, Tian H, Zhang Z, Gu J: Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. Carcinogenesis 34, 1265-1272 (2013)

  • [19]Rho JH, Qin S, Wang JY, Roehrl MH: Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J Proteome Res 7, 2959-2972 (2008)

  • [20]Yanagawa T, Iwasa S, Ishii T, Tabuchi K, Yusa H, Onizawa K, Omura K, Harada H, Suzuki H, Yoshida H: Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 156, 27-35 (2000)

  • [21]Fujita Y, Nakanishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A, Shimizu A, Tanigawa N: Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 12, 6415-6420 (2006)

  • [22]Sofiadis A, Becker S, Hellman U, Hultin-Rosenberg L, Dinets A, Hulchiy M, Zedenius J, Wallin G, Foukakis T, Höög A, Auer G, Lehtiö J, Larsson C: Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol 166, 657-667 (2012)

  • [23]Somiari RI, Sullivan A, Russell S, Somiari S, Hu H, Jordan R, George A, Katenhusen R, Buchowiecka A, Arciero C, Brzeski H, Hooke J, Shriver C: High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 3, 1863-1873 (2003)

  • [24]Cha MK, Suh KH, Kim IH: Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res 28, 93 (2009)

  • [25]Sova H, Kangas J, Puistola U, Santala M, Liakka A, Karihtala P: Down-regulation of 8-hydroxydeoxyguanosine and peroxiredoxin II in the pathogenesis of endometriosis-associated ovarian cancer. Anticancer Res 32, 3037-3044 (2012)

  • [26]Kim K, Yu M, Han S, Oh I, Choi YJ, Kim S, Yoon K, Jung M, Choe W: Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep 21, 1391-1396 (2009)

  • [27]Li L, Zhang YG, Chen CL: Anti-apoptotic role of peroxiredoxin III in cervical cancer cells. FEBS Open Bio 3, 51-54 (2012)

  • [28]Hu JX, Gao Q, Li L: Peroxiredoxin 3 is a novel marker for cell proliferation in cervical cancer. Biomed Rep 1, 228-230 (2013)

  • [29]Safaeian M, Hildesheim A, Gonzalez P, Yu K, Porras C, Li Q, Rodriguez AC, Sherman ME, Schiffman M, Wacholder S, Burk R, Herrero R, Burdette L, Chanock SJ, Wang SS: Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer. PLoS One 7, e33619 (2012)

  • [30]Lomnytska MI, Becker S, Bodin I, Olsson A, Hellman K, Hellström AC, Mints M, Hellman U, Auer G, Andersson S: Differential expression of ANXA6, HSP27, PRDX2, NCF2, and TPM4 during uterine cervix carcinogenesis: diagnostic and prognostic value. Br J Cancer 104, 110-119 (2011)

  • [31]Zou S, Shen Q, Hua Y, Jiang W, Zhang W, Zhu X: Proteomic identification of neoadjuvant chemotherapy-related proteins in bulky stage IB-IIA squamous cervicalcancer. Reprod Sci 20, 1356-1364 (2013)

  • [32]He T, Banach-Latapy A, Vernis L, Dardalhon M, Chanet R, Huang ME: Peroxiredoxin 1 knockdown potentiates β-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals. Carcinogenesis 34, 760-769 (2013)

  • [33]Lee JY, Jung HJ, Song IS, Williams MS, Choi C, Rhee SG, Kim J, Kang SW: Protective role of cytosolic 2-cys peroxiredoxin in the TNF-alpha-induced apoptotic death of human cancer cells. Free Radic Biol Med 47, 1162-1171 (2009)

  • [34]Moon JC, Hah YS, Kim WY, Jung BG, Jang HH, Lee JR, Kim SY, Lee YM, Jeon MG, Kim CW, Cho MJ, Lee SY: Oxidative stress-dependent structural and functional switching of a human 2-Cys peroxiredoxin isotype II that enhances HeLa cell resistance to H2O2-induced cell death. J Biol Chem 280, 28775-28784 (2005)

  • [35]Yue QX, Song XY, Ma C, Feng LX, Guan SH, Wu WY, Yang M, Jiang BH, Liu X, Cui YJ, Guo DA: Effects of triterpenes from Ganoderma lucidum on protein expression profile of HeLa cells. Phytomedicine 17, 606-613 (2010)

  • [36]Liang S, Singh M, Gam LH: Potential hydrophobic protein markers of breast cancer in Malaysian Chinese, Malay and Indian patients. Cancer Biomark 8, 319-330(2010-2011)

  • [37]Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, Chae HZ: Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21, 2085-2090 (2001)

  • [38]Tehan L, Taparra K, Phelan S: Peroxiredoxin overexpression in MCF-7 breast cancer cells and regulation by cell proliferation and oxidative stress. Cancer Invest 31, 374-384 (2013)

  • [39]Goncalves K, Sullivan K, Phelan S: Differential expression and function of peroxiredoxin 1 and peroxiredoxin 6 in cancerous MCF-7 and noncancerous MCF-10A breast epithelial cells. Cancer Invest 30, 38-47 (2012)

  • [40]Bae JY, Ahn SJ, Han W, Noh DY: Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines. J Cell Biochem 101, 1038-1045 (2007)

  • [41]Chua PJ, Lee EH, Yu Y, Yip GW, Tan PH, Bay BH: Silencing the Peroxiredoxin III gene inhibits cell proliferation in breast cancer. Int J Oncol 36, 359-364 (2010)

  • [42]Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res 9, 3418-3424 (2003)

  • [43]Woolston CM, Storr SJ, Ellis IO, Morgan DA, Martin SG: Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer. Radiother Oncol 100, 308-313 (2011)

  • [44]España L, Martín B, Aragüés R, Chiva C, Oliva B, Andreu D, Sierra A: Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis. Am J Pathol 167, 1125-1137 (2005)

  • [45]Stresing V, Baltziskueta E, Rubio N, Blanco J, Arriba MC, Valls J, Janier M, Clézardin P, Sanz-Pamplona R, Nieva C, Marro M, Petrov D, Sierra A: Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene 32, 724-735 (2013)

  • [46]Karihtala P, Kauppila S, Soini Y, Arja-Jukkola-Vuorinen: Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-likebreast carcinomas. BMC Cancer 11, 262 (2011)

  • [47]Li DQ, Wang L, Fei F, Hou YF, Luo JM, Wei-Chen, Zeng R, Wu J, Lu JS, Di GH, Ou ZL, Xia QC, Shen ZZ, Shao ZM: Identification of breast cancer metastasis-proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 6, 3352-3368 (2006)

  • [48]Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 9, R76 (2007)

  • [49]Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F, Celis JE: Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol 4, 65-89 (2010)

  • [50]Liu FJ, Wang XB, Cao AG: Screening and functional analysis of a differential protein profile of human breast cancer. Oncol Lett 7, 1851-1856 (2014)

  • [51]Kalinina EV, Berezov TT, Shtil’ AA, Chernov NN, Glazunova VA, Novichkova MD, Nurmuradov NK: Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation. Bull Exp Biol Med 153, 878-881 (2012)

  • [52]Smith L, Welham KJ, Watson MB, Drew PJ, Lind MJ, Cawkwell L: The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol Res 16, 497-506 (2007)

  • [53]Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23, 422-431 (2005)

  • [54]McDonald C, Muhlbauer J, Perlmutter G, Taparra K, Phelan SA: Peroxiredoxin proteins protect MCF-7 breast cancer cells from doxorubicin-induced toxicity. Int J Oncol 45, 219-226 (2014)

  • [55]He J, Whelan SA, Lu M, Shen D, Chung DU, Saxton RE, Faull KF, Whitelegge JP, Chang HR: Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response. Int J Proteomics 2011, 896476 (2011)

  • [56]Liu X, Feng R, Du L: The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breastcancer MCF-7 cells. FEBS Lett 584, 3185-3192 (2010)

  • [57]Lee SU, Rhee Mc, Min YK, Kim SH: Involvement of peroxiredoxin IV in the 16alpha-hydroxyestrone-induced proliferation of human MCF-7 breast cancer cells. Cell Biol Int 32, 401-405 (2008)

  • [58]Wang T, Tamae D, LeBon T, Shively JE, Yen Y, Li JJ: The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res 65, 10338-10346 (2005)

  • [59]Diaz AJ, Tamae D2, Yen Y3, Li J4, Wang T: Enhanced radiation response in radioresistant MCF-7 cells by targeting peroxiredoxin II. Breast Cancer (Dove Med Press) 5, 87-101 (2013)

  • [60]Tang HY, Beer LA, Chang-Wong T, Hammond R, Gimotty P, Coukos G, Speicher DW: A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. J Proteome Res 11, 678-691 (2012)

  • [61]Wang XY, Wang HJ, Li XQ: Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer. Tumour Biol 34, 2275-2281 (2013)

  • [62]Hoskins ER, Hood BL, Sun M, Krivak TC, Edwards RP, Conrads TP: Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation. PLoS One 6, e25056 (2011)

  • [63]Pak JH, Choi WH, Lee HM, Joo WD, Kim JH, Kim YT, Kim YM, Nam JH: Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest 29, 21-28 (2011)

  • [64]Han S, Shen H, Jung M, Hahn BS, Jin BK, Kang I, Ha J, Choe W: Expression and prognostic significance of human peroxiredoxin isoforms in endometrial cancer. Oncol Lett 3, 1275-1279 (2012)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jun 2016Review

Expression and function of peroxiredoxins in gynecological malignancies

Wenwen Zhang 1, Qingfeng Zhou 1, Xuejiao Tao 1, Zhaojun Shen 1, Hui Luo 1, Xueqiong Zhu 1,*
Affiliation
Article Info

1 Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China

Abstract

A large family of peroxiredoxin proteins plays essential roles in the regulation of multiple redox-sensitive cellular activities related to cell signaling, cell proliferation and apoptosis. The involvement of these proteins in protecting cells from oxidative damage, induced by reactive oxygen species, points to their potential role in human cancers. According to some studies, the peroxiredoxin proteins in gynecological malignancies, promote tumors development and progression, whereas others indicate that peroxiredoxin proteins function as onco-suppressors in these cancers. Here, we review the utilization of peroxiredoxin proteins as novel biomarkers for screening and early diagnosis of gynecological malignancies, and as the specific therapy targets and prognostic factors as well.

Keywords

  • Peroxiredoxins
  • Gynecological Malignancies
  • Review

References